President Biden blocks Nippon Steel's $15 billion acquisition of U.S. Steel, citing national security concerns and the commitment to bolster domestic production.
In 2025, Big Pharma plans to pursue acquisitions to replace lost revenue from expiring patents on major drugs, focusing on obesity and oncology markets.
President Biden is set to announce his decision on Nippon Steel's acquisition of U.S. Steel, which carries significant implications for American steel production.